Tesamorelin 11 mg + Ipamorelin 6 mg is a combined investigational compound belonging to the class of synthetic peptides, chemically a composition of a 44-amino acid GHRH analog and a pentapeptide secretagogue. Within scientific research, this combination is studied as a model compound for receptor and signal transduction research and as a reference standard in analytical work. This compound is offered as a freeze-dried vial containing a total of 17 mg, exclusively for laboratory and research purposes.<\/p>\n
Tesamorelin (development code TH9507) is a synthetic analog of growth hormone-releasing hormone and consists of the full 44-amino acid sequence GHRH(1\u201344), with a trans-3-hexenoyl group covalently linked to the N-terminal tyrosine. This acyl modification makes the molecule less susceptible to cleavage by dipeptidylpeptidase-4 (DPP-4). Ipamorelin (development code NNC 26-0161), on the other hand, is a pentapeptide with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2<\/sub>, composed of partly non-natural and D-amino acids with an amidated C-terminus \u2014 a structure that makes it structurally stable.<\/p>\n In research models, both components have their own biochemical target. In vitro, tesamorelin behaves as a full agonist of the GHRH receptor, a class B G-protein-coupled receptor that acts via Gs<\/sub> directs the formation of cyclic AMP. In cell models, ipamorelin binds selectively to the secretagogue receptor GHS-R1a, which via Gq\/11<\/sub> Phospholipase C activates, with the formation of inositol trisphosphate and mobilization of intracellular calcium. Two distinct receptor systems in a single preparation make the combination suitable for research into converging pathways. Consequently, Tesamorelin + Ipamorelin is used as a model compound and reference substance within scientific research.<\/p>\n In a laboratory context, Tesamorelin + Ipamorelin occurs in the following research areas, among others:<\/p>\n Vsaka od teh aplikacij vklju\u010duje nadzorovane laboratorijske ali predklini\u010dne modelne raziskave.<\/p>\n Within our range, this vial falls under the category of combined investigational compounds: preparations in which two peptides are combined in a fixed ratio in a single freeze-dried unit. Researchers choose this type when two targets are studied side-by-side in the same model system. Other compound compounds within the same product line are built around entirely different enzymatic or receptor-bound targets; they share the freeze-dried vial form but differ in molecular class and investigated mechanism.<\/p>\n The preparation is supplied as a lyophilized powder in a glass vial, containing 17 mg total: 11 mg Tesamorelin and 6 mg Ipamorelin. Unlike a solid tablet form, a lyophilisate is intended to be placed in a suitable solvent in the laboratory; the material is more stable in a dry state.<\/p>\n Store the vial refrigerated, protected from light and moisture, in the original packaging. Handle the compound with standard laboratory precautions: work in a clean environment, use appropriate personal protective equipment, and prevent cross-contamination. Avoid repeated temperature changes and keep the packaging out of reach of unauthorized persons.<\/p>\n For this freeze-dried preparation, a controlled purity of \u2265 99% (HPLC) is maintained for the individual peptide components. The relative proportions of the components are also fixed, so that the composition is known during analytical work.<\/p>\nRaziskovalna podro\u010dja<\/h2>\n
\n
Tesamorelin + Ipamorelin in our research assortment<\/h2>\n
Specifikacije<\/h2>\n
\n\n
\n \nSpecifikacija<\/th>\n Vrednost<\/th>\n<\/tr>\n<\/thead>\n \n Vzorec<\/td>\n Tesamorelin + Ipamorelin (combined preparation)<\/td>\n<\/tr>\n \n Sinonimi<\/td>\n Tesamorelin: (3E)-hex-3-enoylsomatoliberine; TH9507. Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2<\/sub>; NNC 26-0161<\/td>\n<\/tr>\n \n \u0160tevilka CAS<\/td>\n 218949-48-5 (Tesamorelin) 170851-70-4 (Ipamorelin)<\/td>\n<\/tr>\n \n Molekulska formula \/ te\u017ea<\/td>\n C221<\/sub>H366<\/sub>N72<\/sub>O67<\/sub>S \/ 5135.9 Da \u00b7 C38<\/sub>H49<\/sub>N9<\/sub>O5<\/sub> \/ 711,9 Da<\/td>\n<\/tr>\n \n PubChem CID<\/td>\n 16137828 (Tesamorelin) 9831659 (Ipamorelin)<\/td>\n<\/tr>\n \n Razred<\/td>\n Synthetic peptides; GHRH receptor agonist and selective GHS-R1a agonist<\/td>\n<\/tr>\n \n Obrazec<\/td>\n Lyophilized powder (freeze-dried powder) in glass vial<\/td>\n<\/tr>\n \n Koli\u010dina na vialo<\/td>\n 17 mg total (Tesamorelin 11 mg, Ipamorelin 6 mg)<\/td>\n<\/tr>\n \n Shranjevanje<\/td>\n Hranite v hladilniku, za\u0161\u010diteno pred svetlobo in vlago<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n Oblika, ravnanje in shranjevanje<\/h2>\n
Sestava in laboratorijski rezultati<\/h2>\n